Everest Medicines Announces Participation in September Investor Conferences
SHANGHAI, Aug. 25, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced thatIan Woo, President and Chief Fin...
Etrasimod Receives Strong Recommendation in the ACG Clinical Guideline Update: Ulcerative Colitis in Adults for Induction and Maintenance Phase of Moderately to Severely Active UC
Shanghai, Aug. 15, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that etrasimod (VELSIPITY®) has be...
Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY® by the Taiwan Food and Drug Administration for the Treatment of Moderately to Severely Active Ulcerative Colitis
SHANGHAI, Aug. 14, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that the Taiwan Food and Drug Adminis...
Everest Medicines to Announce 2025 Interim Results on August 29, 2025
SHANGHAI, Aug. 11, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that it will report its interim resul...
Everest Medicines Announces Full Approval of NEFECON® in Taiwan
SHANGHAI, Aug. 6, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced the Taiwan Food and Drug Administrati...
Everest Medicines Expands Strategic Investment in I-MAB
- Everest will invest US$30.9 million (equivalent to approximately HK$242.6 million) in cash in I-Mab. Inclusive of I-MAB shares already held by Everest, the pro forma ownership will be 16.1%. - I-Mab's Claudin 18.2 x 4-1BB bispecific antibody, givastomig, demonstrated an impressive overall resp...
Everest Medicines Announces Share Placement to Raise Approximately HK$1,572.50 Million
SHANGHAI, July 25, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest" or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it has entered into a placing and...
Everest Medicines Showcases Breakthroughs in Proprietary AI-Powered mRNA Platform at 2025 R&D Day Held in Shanghai
SHANGHAI, July 4, 2025 /PRNewswire/ -- Everest Medicines (HKEX: 1952.HK), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative medicines, recently hosted the "2025 Everest Medicines mRNA Platform R&D Day" in Shanghai. The e...
Everest Medicines Announces Updated Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of EVER001, a Novel BTK Inhibitor for the Treatment of Primary Membranous Nephropathy
* As of March 21st, 2025, longer follow-up data was collected from the ongoing Ph1b/2a study of EVER001: in Cohort 1, 11 patients completed 52 weeks of follow-up. In Cohort 2, 7 patients completed 52 weeks of follow-up. * The updated data showed that EVER001 was well-tolerated and efficacious ...
Everest Medicines Announces Official Publication of the Specifications for Antimicrobial Susceptibility Testing of Eravacycline (2025)
SHANGHAI, June 23, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that theSpecifications for Antimicro...
Everest Medicines Announces Successful Release of First Clinical Batch of Tumor-Associated Antigen Vaccine EVM14 at Jiashan Manufacturing Site
SHANGHAI, June 20, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced the successful release of the first ...
Everest Medicines Presents Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of Novel BTK Inhibitor EVER001 at the 62nd Congress of the European Renal Association
* EVER001 is a covalent reversible BTK inhibitor with potentially best-in-class characteristics for the treatment of primary membranous nephropathy (pMN) and other autoimmune renal diseases, including IgA nephropathy (IgAN), minimal change disease (MCD), focal segmental glomerulosclerosis (FSG...
NEFECON®: New Results at ERA 2025 Demonstrate Treatment Benefit of the 'Treat Early' Strategy
* Two new studies on NEFECON® demonstrate its treatment benefit in the "Treat Early" strategy for IgA nephropathy (IgAN), providing robust support for the new disease management strategy: "Treat the Cause, Treat Early, Treat All": — A subanalysis of the NefIgArd study demonstrates that early tr...
Everest Medicines Announces NEFECON® Inclusion in China's Clinical Practice Guideline for IgA Nephropathy and IgA Vasculitis in Chinese Adults (For Public Review)
SHANGHAI, May 23, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics,announced that NEFECON® has been included in the "Clin...
Everest Medicines Announces NMPA Full Approval of NEFECON® for the Treatment of Primary Immunoglobulin A nephropathy (IgAN) in Adults at Risk of Disease Progression
SHANGHAI, May 7, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that the supplemental New Drug Applica...
Everest Medicines Announces New Drug Application Approval of VELSIPITY® for Adults with Moderately to Severely Active Ulcerative Colitis in Hong Kong
SHANGHAI, April 30, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that the Department of Health of the...
Everest Medicines Announces the "B" Marker Removal from Company's Stock Code, Effective May 2, 2025
SHANGHAI, April 28, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that the "B" marker will cease to be...
Everest Medicines Announces Approval of "B" Marker Removal from Company's Stock Code by the Hong Kong Stock Exchange
SHANGHAI, April 22, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that The Stock Exchange of Hong Kong...
Everest Medicines Announces Financial Results for Full Year Ended December 31, 2024
SHANGHAI, March 26, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative medicines and vaccines, today announced its financial results for ...
Everest Medicines Announces FDA Clearance of IND Application for Tumor-Associated Antigen Vaccine EVM14
* EVM14 received U.S. FDA clearance for its IND application, becoming Everest's first internally discovered program, and the first mRNA therapeutic cancer vaccine to be cleared for global clinical development. * Preclinical highlights： * EVM14 induced a dose-dependent, antigen-specific immun...
